Original Article

Relationship Between Serum Osteocalcin Levels and Glycosylated Hemoglobin in Type II Diabetes Patients

Maria Mufti1, Nida Khaliq2, Mehtab Munir3, Almas Khattak4, Arsalan Mufti5, Fakeha Ansari6, Bilkis Hassan6 and Farrukh Ansar7

ARTICLE INFO

Key Words: Osteocalcin levels, HbA1c levels, Type 2 Diabetes Mellitus

How to Cite: Mufti, M., Khaliq, N., Munir, M., Khattak, A., Mufti, A., Ansari, F., Hassan, B., & Ansar, F. (2022). Relationship Between Serum Osteocalcin Levels and Glycosylated Hemoglobin in Type II Diabetes Patients: Osteocalcin Levels and Glycosylated Hemoglobin in Diabetes Patients. Pakistan Journal of Health Sciences, 3(06). https://doi.org/10.54393/pjhs.v3i06.369

*Corresponding Author: Farrukh Ansar Quaid e Azam International Hospital, Islamabad, Pakistan farrukhanser@gmail.com

Received Date: 17th October, 2022
Acceptance Date: 21st November, 2022
Published Date: 30th November, 2022

ABSTRACT

Diabetic osteopathy is a complication of diabetes that elevates the risk of bone fractures and influences bone remodeling. Osteocalcin is a bone protein produced by osteoblasts that plays a role in the regulation of glucose and energy metabolism. Objectives: To explore the relationship between the level of glycosylated hemoglobin (HbA1c) and osteocalcin in diabetic patients.

Methods: This cross-sectional analytical study was carried out at Hayatabad Medical Complex, Peshawar from January 2017 to February 2018. A total of 100 patients suffering from Type 2 Diabetes Mellitus (T2DM) were recruited. HbA1c and osteocalcin levels were measured by the enzymatic method and electrochemiluminescence immunoassay, respectively. SPSS was utilized for data entry and analysis; Pearson's correlation was performed to assess the relationship between variables while statistical significance was accepted at p < 0.05.

Results: The mean (SD) age of participants was 50 (9.2), while 58% of the study population was female. The mean (SD) HbA1c and osteocalcin levels were 11.3 (8.8) and 13.1 (6.8), respectively. The results of the correlation analysis yielded a negative relationship between HbA1c and osteocalcin levels (r =-0.099), but the results were statistically non-significant (p-value =0.328).

Conclusion: Our study suggested that osteocalcin level has a negative correlation with HbA1c level in Type 2 Diabetes Mellitus patients.

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is a chronic ailment in which the body shows resistance to insulin where target cells are unable to react normally to insulin. Nutritional control and oral hypoglycemics are useful in treatment, but eventually, a patient needs insulin therapy [1]. According to data from 2010 studies, approximately 285 million individuals, constituting roughly six percent of the global population, were suffering from diabetes. Amongst them, 20% of the current diabetic population resides in Southeast Asia. The number of diabetics in developed countries is likely to triple by the year 2025 [2]. In 1980, approximately 108 million individuals were living with diabetes worldwide. However, this number increased to 422 million in 2014. Since 1980, the prevalence of diabetes in the general population has increased by nearly twofold, from 4.7% to 8.5%. This indicates a rise in risk factors like
obesity and sedentary lifestyles. As per statistics of 2012, diabetes contributed to over one and half million fatalities. It is predicted that developing countries will endure the most of this epidemic in the 21st century [3]. Osteocalcin (BGLAP-bone gamma-carboxyglutamic acid-containing protein) is a non-collagen protein hormone found in dentin and bone because it has a Gla domain. Osteocalcin is encoded by the BGLAP gene and its receptors are GPRC6A [4]. Serum osteocalcin levels are a predictor of bone formation and its negative metabolic consequences. Various articles show an inverse association between adverse metabolic outcomes and serum osteocalcin, suggesting that osteocalcin levels should be maintained at normal levels in diabetic patients [5]. Recent studies conclude that serum osteocalcin has a positive role in glucose metabolism and fat accumulation. Osteocalcin works like a hormone in the human body, stimulating beta cells of the pancreas to secrete more insulin, and also direct fat cells to secrete the hormone adiponectin, which also increases its sensitivity to insulin. Osteocalcin alters insulin release and sensitivity, β-cell proliferation, and energy metabolism [6-7]. Uncarboxylated osteocalcin (ucOC) improves insulin sensitivity and enhances insulin release, which has been proven by clinical trials on animal models. Principally, human trials have shown that there is a decrease in total osteocalcin (TOC) values, which is linked with exacerbated glycemic control and insulin resistance [8-10]. This study was aimed to determine HbA1c and osteocalcin levels in diabetic (T2DM) patients and to find out if there were any potential relationships between them.

METHODS

This cross-sectional study was conducted at Hayatabad Medical Complex (HMC), a public tertiary care hospital situated in Peshawar, Pakistan. The study duration was one year (January 2017 to February 2018), and ethical approval was granted by the Post Graduate Medical Education department, Khyber Girls Medical College (Ref No. 1831/PGMED/KGMC). A total of 100 participants were selected, who were presented to the Medical and Endocrinology department of HMC. Patients already diagnosed with T2DM were included in the study. The criteria for T2DM were based on the American Diabetes Association guidelines, which stated that diabetes was diagnosed when fasting plasma glucose was 7.0 mmol/L, or 2-hour oral glucose tolerance test (OGTT) was 11.1mmol/L, or HbA1c was 6.5%. However, any patient who was suspected or diagnosed with a disease that could potentially alter bone metabolism was excluded. Patients with cushing syndrome, acromegaly, thyroid disease, osteoporosis, ankylosing spondylitis, rheumatoid arthritis, hyperparathyroidism, liver failure, chronic kidney disease, and other similar conditions were deemed ineligible for the study. Patients who were on corticosteroids, synthetic hormones, or bisphosphonates were also excluded from the study. A detailed history and clinical examination were performed, and the patient’s files were reviewed in detail to strictly meet the inclusion criteria. Participants were informed about the nature and purposes of the study, and a written consent form was also signed. All participants were assured of their confidentiality and were given the option to withdraw from the research at any time. Furthermore, no monetary remuneration was provided to individuals for their participation in the study. Fasting blood samples were collected, centrifuged, and stored at -25° C until analysis. The blood specimens were then sent to the Pathology Department at Rehman Medical Institute (RMI), Peshawar because of the availability of standard kits and laboratory services needed for the present study. Glycosylated hemoglobin Alc (HbA1c) was measured utilizing EDTA (Ethylenediamine tetraacetic acid) tubes through an enzymatic method using ARCHITECT ci8200 (Abbott®, Abbott Park, Illinois, U.S.A) while serum osteocalcin concentration was measured using an electrochemiluminescence immunoassay (Cobas 601, Roche Diagnostics). SPSS version 22.0 (SPSSInc., Chicago, IL) was used for data entry and analysis. Data entry was performed by research assistants and was cross-checked by other members for any potential errors. Where appropriate, descriptive statistics were presented as means, standard deviations, and percentages. Pearson’s correlation test was performed to find out any potential relationship between study variables. For statistical significance, a p-value of < 0.05 and a 95% confidence interval were considered significant.

RESULTS

There were 100 participants in the present study. The mean (SD) age of the study subjects was 50 (9.2) (range: 40-65 years). 28% of patients were in the age range of 40–45 years; 32% of patients were in the age range of 46–55 years; and 40% of patients were in the age range of 55–65 years. Gender wise, 58% of the participants were female and 42% were male.

| Variable | Total | Male | Female |
|----------|-------|------|--------|
| Age | 50 ± 9.2 years | 48 ± 6.3 | 52 ± 7.6 |
| Duration of T2D | 9.76 ± 4.2 years | 9.2 ± 3.8 | 9.98 ± 4.8 |
| MBMI | 28.56 ± 3.1 | 28.11 ± 2.2 | 28.96 ± 2.9 |
| Comorbidities | | | |
| Hypertension | 62 | 27 | 35 |
| Cardiovascular disease | 34 | 16 | 18 |
| Obesity | 73 | 34 | 39 |
| Osteoporosis | 16 | 3 | 13 |
It is generally acknowledged that Type II diabetes mellitus is a complicated metabolic disorder driven by the combination of several factors, including hereditary, ecological, and lifestyle factors. In multiple studies, researchers have suggested that in individuals with Type II diabetes mellitus, serum osteocalcin was linked with glucose tolerance [10-11]. Osteopathy related to diabetes is one of the most crucial problems and needs prompt intervention as it may lead to an increased risk of bone fracture and ill adaptation of bone metabolism. Osteocalcin is one of the bone proteins that plays an important role in bone metabolism and maintains bone density and integrity. From a metabolic perspective, osteoblasts produce osteocalcin, which was involved in glucose metabolism and produces energy in the form of Adenosine Tri-Phosphate (ATPS). However, in diabetes, the deranged metabolism leads to a decrease in the osteocalcin levels [12]. HbA1c levels may represent the possible role of osteocalcin in glucose metabolism in patients with type 2 diabetes mellitus. Maddaloni et al., reported that diabetes and osteoporosis are two very common diseases with a great socio-economic impact [13]. Patients with Type-2 diabetes mellitus have altered bone density and have an increased risk of bone fractures. The results of osteoporosis treatment in patients with diabetes are not satisfactory [14]. An HbA1c of 48 mmol/mol (6.5%) is considered as the cut-off point for diagnosing diabetes. HbA1c less than 48 mmol/mol (6.5%) necessitates additional testing, such as oral glucose tolerance tests (OGTT) [15]. The results indicate that the mean serum osteocalcin level was 13. 13 ± 6.899 ng/ml (reference values for > 18 years: 9–38 ng/mL) while the mean HbA1c 11.36 ± 8.862% (reference value > 6.5%).

**Table 1:** Baseline characteristics of study population

| Medications       | Total | Male | Female |
|-------------------|-------|------|--------|
| Sulfonylureas     | 46    | 20   | 26     |
| Metformin         | 67    | 30   | 37     |
| Insulin           | 33    | 21   | 12     |

Table 2: Mean and median of variables

As indicated from the descriptive statistics, the mean serum osteocalcin and HbA1c levels were 13 (6.8) ng/L and 11% (8.8%) respectively. Pearson’s correlation analysis revealed that there was a weak inverse relationship between serum osteocalcin and HbA1c levels; however, the results were statistically non-significant (r = -0.099, p-value = 0.328) (Figure 1). However, BMI and Age were positively correlated with the HbA1c as shown in (Table 3).

Table 3: Shows correlation between HbA1c and other variables.

| Variable | Total | Male | Female |
|----------|-------|------|--------|
| Serum Osteocalcin | -0.099 | 0.328 | -0.121 | 0.541 | -0.091 | 0.046 |
| BMI      | 0.324 | 0.046 | 0.312 | 0.061 | 0.341 | 0.048 |
| Age      | 0.181 | 0.112 | 0.172 | 0.213 | 0.189 | 0.096 |

**DISCUSSION**

It is generally acknowledged that Type II diabetes mellitus is a complicated metabolic disorder driven by the combination of several factors, including hereditary, ecological, and lifestyle factors. In multiple studies, researchers have suggested that in individuals with Type II diabetes mellitus, serum osteocalcin was linked with glucose tolerance [10-11]. Osteopathy related to diabetes is one of the most crucial problems and needs prompt intervention as it may lead to an increased risk of bone fracture and ill adaptation of bone metabolism. Osteocalcin is one of the bone proteins that plays an important role in bone metabolism and maintains bone density and integrity. From a metabolic perspective, osteoblasts produce osteocalcin, which was involved in glucose metabolism and produces energy in the form of Adenosine Tri-Phosphate (ATPS). However, in diabetes, the deranged metabolism leads to a decrease in the osteocalcin levels [12]. HbA1c levels may represent the possible role of osteocalcin in glucose metabolism in patients with type 2 diabetes mellitus. Maddaloni et al., reported that diabetes and osteoporosis are two very common diseases with a great socio-economic impact [13]. Patients with Type-2 diabetes mellitus have altered bone density and have an increased risk of bone fractures. The results of osteoporosis treatment in patients with diabetes are not satisfactory [14]. An HbA1c of 48 mmol/mol (6.5%) is considered as the cut-off point for diagnosing diabetes. HbA1c less than 48 mmol/mol (6.5%) necessitates additional testing, such as oral glucose tolerance tests (OGTT) [15]. The results indicate that the mean serum osteocalcin level was 13. 13 ± 6.899 ng/ml (reference values for > 18 years: 9–38 ng/mL) while the mean HbA1c 11.36 ± 8.862% (reference value > 6.5%).
indicating that almost all of them have chronic diabetic conditions. While the mean osteocalcin level was within an acceptable range, the median of data showed that 50% of the samples had osteocalcin levels greater than 15 ng/ml, indicating increased bone turnover. John et al., revealed that in cases of type 2 diabetes, osteoblastic activities of the bone forming cells/tissue are impaired, but the reabsorption remains normal or improved [16]. The osteocalcin level in the present study also supports this mechanism as shown from the range which comes under the reference range. However, most of the results are skewed toward the upper border of the reference ranges. HbA1c was found to be inversely related to osteocalcin (r = 0.099, p = 0.328). Bao et al., which demonstrates a raised osteocalcin level in serum (p = 0.014), while parameters identified with glucose variability, the standard deviation of plasma glucose values, and mean adequacy of glycemic expedition (MAGE), diminished fundamentally (p < 0.001) after treating patients for 8 weeks [17]. At standard, the connection between homeostatic model appraisal of β-cell capacity (P = 0.048) and fasting C-peptide levels and serum osteocalcin levels (p = 0.004) was positive. However, the relationship between serum osteocalcin levels and 24 h mean blood glucose (P < 0.001), HbA1c (p = 0.020) and fasting plasma glucose (p = 0.023) was negative. It was concluded that serum osteocalcin foci expanded with enhanced glucose control. Gundberg et al., reported that changes in glucose variability (controlling glucose) by hypoglycemic agents were linked with early high levels of osteocalcin (i.e., maintaining serum osteocalcin level) [18]. This indicates that osteocalcin could be used to enhance the glucose-related metabolism aspect of energy regulation. Previous research found that osteocalcin was strongly linked to carbohydrate metabolism due to changes in pancreatic cell (β-cell) proliferation and increased insulin sensitivity [19]. In Gu et al., study animal model has shown similar results and reported cognitive impairment in subjects with decreased serum osteocalcin levels [20]. However, a proper clinical trial on an animal model is required to see the effect of osteocalcin therapy among diabetic subjects. The current results cannot be generalized; however, they can be used as a basis for further research.

CONCLUSIONS

The present study suggested that osteocalcin level has a negative correlation with HbA1c level in Type 2 Diabetes Mellitus patients. The poor control of diabetes can significantly lead to diabetic osteopathy, and patients can experience different bone disorder, including bone deformity, frequent fractures, and limited bone turnover.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

SOURCE OF FUNDING

The author(s) received no financial support for the research, authorship and/or publication of this article

REFERENCES

[1] Hwang YC, Kang M, Cho IJ, Jeong IK, Ahn KJ, Chung HY, et al. Association between the circulating total osteocalcin level and the development of cardiovascular disease in middle-aged men: a mean 8.7-year longitudinal follow-up study. Journal of Atherosclerosis and Thrombosis. 2015 Feb; 22(2): 136-43. doi: 10.5551/jat.25718

[2] Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Scientific Reports. 2020 Sep; 10(1): 1-11. doi: 10.1038/s41598-020-71908-9

[3] World Health Organization. Global report on diabetes. 2016. [Last Cited on: 29th November 2022] Available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf

[4] Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone. 2016 Jan; 82: 42-9. doi: 10.1016/j.bone.2015.05.046

[5] Kunutsor SK, Apekey TA, Laukkkanen JA. Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. European journal of epidemiology. 2015 Aug; 30(8): 599-614. doi: 10.1007/s10654-015-0058-x

[6] Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007 Aug; 130(3): 599-614. doi: 10.1016/j.cell.2007.05.047

[7] Lerchbaum E, Schwetz V, Nauck M, Völzke H, Wallaschofski H, Hannemann A. Lower bone turnover markers in metabolic syndrome and diabetes: the population-based Study of Health in Pomerania. Nutrition, Metabolism and Cardiovascular Diseases. 2015 May; 25(5): 458-63. doi: 10.1016/j.numecd.2015.02.002

[8] Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice. 2014 Oct; 2014: 1-22. doi: 10.1155/2014/943162

[9] Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. The Journal of Sexual Medicine. 2015 Apr; 12(4): 856-75. doi: 10.1111/jsm.12828

[10] Chen Y, Zhao Q, Du G, Xu Y. Association between serum osteocalcin and glucose/lipid metabolism in
Chines Han and Uygur populations with type 2 diabetes mellitus in Xinjiang: two cross-sectional studies. Lipids in Health and Disease. 2017 Dec; 16(1): 1-0. doi: 10.1186/s12944-017-0512-8

[11] Nyman JS, Even JL, Jo CH, Herbert EG, Murry MR, Cockrell GE, et al. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone. 2011 Apr; 48(4): 733-40. doi: 10.1016/j.bone.2010.12.016

[12] Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi-Hashi am A, et al. Metabolic syndrome and its components among rheumatoid arthritis patients: a comprehensive updated systematic review and meta-analysis. PLoS one. 2017 Mar; 12(3): e0170361. doi: 10.1371/journal.pone.0170361

[13] Maddaloni E, D’Onofrio L, Lauria A, Maurizi AR, Strollo R, Palermo A, et al. Osteocalcin levels are inversely associated with HbA1c and BMI in adult subjects with long-standing type 1 diabetes. Journal of Endocrinological Investigation. 2014 Jul; 37(7): 661-6. doi: 10.1007/s40618-014-0092-7

[14] Wang Q, Zhang B, Xu Y, Xu H, Zhang N. The relationship between serum osteocalcin concentration and glucose metabolism in patients with type 2 diabetes mellitus. International Journal of Endocrinology. 2013 Oct; 2013: 1-8. doi: 10.1155/2013/842598

[15] Sultan E, Taha I, Saber LM. Altered bone metabolic markers in type 2 diabetes mellitus: Impact of glycemic control. Journal of Taibah University Medical Sciences. 2008 Jan; 3(2): 104-16. doi: 10.1016/S1658-3612(08)70059-3

[16] John WG, Hillson R, Alberti SG. Use of haemoglobin A1c (HbA1c) in the diagnosis of diabetes mellitus. The implementation of World Health Organisation (WHO) guidance 2011. Practical Diabetes. 2012 Jan; 29(1): 12-12a. doi: 10.1002/pdi.1648

[17] Bao YQ, Zhou M, Zhou J, Lu W, Gao YC, Pan XP, et al. Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes. Clinical and Experimental Pharmacology and Physiology. 2011 Jan; 38(1): 50-4. doi: 10.1111/j.1440-1681.2010.05463.x

[18] Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. The Journal of Clinical Endocrinology and Metabolism. 1998 Sep; 83(9): 3258-66. doi: 10.1210/jcem.83.9.5126

[19] Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic